Merck, GSK expand sales forces in China

Share this article:
Merck, GSK expand sales forces in China
Merck, GSK expand sales forces in China

Merck and GlaxoSmithKline are both increasing the number of sales reps operating in China, according to separate presentations given by the two companies. In both cases, added reps in emerging markets are helping to offset significant reductions in US sales forces, company executives said.

Merck's president and CEO Ken Frazier, in a presentation given at the JP Morgan Healthcare Conference on January 11, said sales forces in the US were reduced “by nearly one-third, 32%,” in 2010. “At the same, we were substantially increasing our presence and field force in emerging markets, like China, Brazil and Russia,” said Frazier. A transcript of the presentation is available here.

Overall, global pharmaceutical and vaccine sales forces were reduced by 12% in 2010, according to Frazier, and the company's total sales – year-to-date September 2010 – grew by 3%, he said. That growth came during a period of “maximum disruption,” when Merck was “blending sales forces [with Schering-Plough's reps], training reps on new products and disrupting established customer relationships,” said Frazier.

In a separate presentation given in December, Mark Reilly, GSK's general manager, China and Hong Kong, said GSK had steadily escalated sales force numbers in China; as of March 2010, over 2,500 reps were working in the Chinese market, according to slides from the presentation. GSK ranked 14 in terms of market share in China, at just under 1% of the total share. Pfizer, AstraZeneca, and Sanofi Aventis ranked first, second and third, respectively, with Pfizer's market share holding at less than 3%, according to Reilly's slides.

The GSK presentation was given on December 1, at the CLSA Emerging Markets Healthcare Forum.

Share this article:
close

Next Article in News

Email Newsletters

More in News

Meaningful use not linked to quality: study

Meaningful use not linked to quality: study

A recent study of physicians found no correlation between following EHR meaningful use requirements and providing consistently higher quality of care.

Lilly Q1 sales dip

Lilly Q1 sales dip

US sales fell 34% during the quarter, largely due to lower demand and lower prices for off-patent Cymbalta and Evista.

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...